Market Research Report
Investigation Report on China's Fibrin Sealant (Human) Market, 2018-2022
|Published by||China Research and Intelligence||Product code||762941|
|Published||Content info||30 Pages
Delivery time: 1-2 business days
|Investigation Report on China's Fibrin Sealant (Human) Market, 2018-2022|
|Published: January 2, 2019||Content info: 30 Pages||
Fibrin sealant, also known as fibrin glue, is a biological product commonly used in surgery. Fibrin Sealant (Human) is a blood product that can help treat burn wounds, abdominal incisions in general surgery, incisions in liver surgery, and incisions in vascular surgery by stopping bleeding and covering and sealing wounds.
In China, the accidental deaths and burns rank only second to traffic injuries. And the traffic injuries also include many burns. The annual incidence of burns in China is about 1.5% to 2%, which means that about 20 million people suffer burns every year. And about 5% of the burn victims need hospitalization. From Jan. to Sept. 2018, the number of people discharged from China's medical and health institutions reached 185,577,000, increasing by 6.4% YOY, and a large proportion of the inpatients had surgery. The sales value of Fibrin Sealant (Human) has been rising since the drug was launched in China, reaching about CNY 144 million in 2017. According to CRI's market research, China's Fibrin Sealant (Human) market is dominated by Shanghai RAAS Blood Products Co., Ltd. And Hualan Biological Engineering Inc., and the former has a market share of more than 90% by sales value.
It is expected that in the next few years, with the lifestyle changes brought about by economic development and the rising incidences of various diseases caused by population aging, the number of surgical operations in China will continue to rise, which will help expand the market size of Fibrin Sealant (Human).